ABBV catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2/Phase 3NCT04704921Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDAbbVie · AMDActive, not recruitingABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05955261A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaSt. Jude Children's Research Hospital · Acute Myeloid LeukemiaRecruitingABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06107413Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV)...AbbVie · Unresectable Metastatic Colorectal CancerActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT06468228A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis...AbbVie · Hidradenitis SuppurativaActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT06838845An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely...AbbVie · Ulcerative ColitisRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07219030A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult ParticipantsAbbVie · Healthy VolunteerRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07514260A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese...AbbVie · Healthy VolunteerActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07843693A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersAbbVie · Healthy VolunteersRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 1NCT01479842Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaKami Maddocks, MD · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueActive, not recruitingABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 1/Phase 2NCT06284486A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination...M.D. Anderson Cancer Center · Acute Myeloid LeukemiaRecruitingSNDXCollaboratorABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT01804686A Long-term Extension Study of PCI-32765 (Ibrutinib)Janssen Research & Development, LLC · Chronic Lymphocytic LeukemiaActive, not recruitingJNJLeadABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT04041050A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in...AbbVie · Myeloproliferative NeoplasmActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateEarly Phase 1NCT04161248Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaCanadian Cancer Trials Group · Lymphoma, B-CellActive, not recruitingINCYCollaboratorABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT06672705Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative DisordersTimothy Voorhees · Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderRecruitingGMABCollaboratorABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 2027Sponsor estimatePhase 1NCT04454658Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in...AbbVie · Myelofibrosis (MF)Active, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimateNo phase registeredNCT05916157An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese...AbbVie · Parkinson's Disease (PD)Active, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 2/Phase 3NCT06109272A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in...AbbVie · Hepatocellular CarcinomaActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT06667687Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult...AbbVie · Non-Hodgkin's LymphomaActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 3NCT06701331Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan...AbbVie · Atopic DermatitisActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimateNo phase registeredNCT07284342A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous...AbbVie · Advanced Parkinson's DiseaseRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT07466550A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult ParticipantsAbbVie · Healthy VolunteerRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimatePhase 2NCT04801797Venetoclax + Azacitidine vs. Induction Chemotherapy in AMLMassachusetts General Hospital · Acute Myeloid LeukemiaActive, not recruitingABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT07323641Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerJonsson Comprehensive Cancer Center · Lung Non-Small Cell Carcinoma | ABBVCollaborator | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 2NCT07323641Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerJonsson Comprehensive Cancer Center · Lung Non-Small Cell CarcinomaRecruitingABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 23 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.